Galanis E, Buckner J C, Burch P A, Schaefer P L, Dinapoli R P, Novotny P J, Scheithauer B W, Rowland K M, Vukov A M, Mailliard J A, Morton R F
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
J Clin Oncol. 1998 Sep;16(9):2953-8. doi: 10.1200/JCO.1998.16.9.2953.
Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study.
Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days.
Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/microL in 23% and platelet nadirs less than 25,000/microL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P=.01) and time to progression (P=.008), while PS and grade were the most important predictors of survival (P=.002 and .05, respectively).
This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.
既往研究人员报告,接受氮芥、长春新碱和丙卡巴肼(MOP)治疗的复发性胶质瘤患者中,52%有反应。为证实这些有前景的结果,我们开展了一项II期前瞻性研究。
63例经组织学确诊的复发性胶质瘤患者接受MOP方案治疗。既往接受或未接受过化疗的患者,分别于第1天和第8天静脉注射氮芥3mg/m²或6mg/m²,第1天和第8天静脉注射长春新碱2mg/m²,第1天至第14天口服丙卡巴肼100mg/m²。每28天重复一个周期。
61例可评估反应的患者中,8例有反应(13%),其中1例完全缓解(CR)。反应情况如下:低级别胶质瘤,19%;间变性星形细胞瘤,11%;间变性少突胶质细胞瘤或少突星形细胞瘤,25%;胶质母细胞瘤,4.3%。最常见的毒性是骨髓抑制,23%的患者白细胞最低点低于1000/μL,13%的患者血小板最低点低于25000/μL。2例患者在中性粒细胞减少的情况下死于感染。非血液学毒性包括21%的患者出现神经感觉改变(3%为严重改变),8%的患者出现严重皮肤反应。多因素分析显示,东部肿瘤协作组(ECOG)体能状态(PS)是化疗反应(P = .01)和疾病进展时间(P = .008)的最佳预测指标,而PS和肿瘤分级是生存的最重要预测指标(分别为P = .002和.05)。
本研究未证实既往报道的复发性胶质瘤的高反应率。复发性间变性少突胶质细胞瘤或少突星形细胞瘤以及复发性低级别胶质瘤患者的反应率最高(分别为25%和19%)。多因素分析中,ECOG PS是反应的最佳预测指标,而PS和肿瘤分级是生存的最重要预测指标。